{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:25:51Z","timestamp":1786991151111,"version":"build-2736575974"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.jaad.2023.04.023","type":"journal-article","created":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T01:04:41Z","timestamp":1692061481000},"page":"S33-S35","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"S","title":["Treatment modalities for lymphocytic and neutrophilic scarring alopecia"],"prefix":"10.1016","volume":"89","author":[{"given":"Ogechi","family":"Ezemma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivali","family":"Devjani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen J.","family":"Kelley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryanne M.","family":"Senna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jaad.2023.04.023_bib1","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jdcr.2019.12.008","article-title":"Hair regrowth in 2 patients with recalcitrant central centrifugal cicatricial alopecia after use of topical metformin","volume":"6","author":"Araoye","year":"2020","journal-title":"JAAD Case Rep"},{"issue":"12","key":"10.1016\/j.jaad.2023.04.023_bib2","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.3390\/biomedicines9121755","article-title":"Scarring alopecias: pathology and an update on digital developments","volume":"9","author":"Cummins","year":"2021","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.jaad.2023.04.023_bib3","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1038\/s41467-019-09117-w","article-title":"Genome-wide association study in frontal fibrosing alopecia identifies four susceptibility loci including HLA-B\u221707:02","volume":"10","author":"Tziotzios","year":"2019","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.jaad.2023.04.023_bib4","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1001\/jamainternmed.2017.2762","article-title":"Adverse events reported to the US Food and Drug Administration for cosmetics and personal care products","volume":"177","author":"Kwa","year":"2017","journal-title":"JAMA Intern Med"},{"issue":"4","key":"10.1016\/j.jaad.2023.04.023_bib5","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/bjd.14535","article-title":"Frontal fibrosing alopecia: possible association with leave-on facial skin care products and sunscreens; a questionnaire study","volume":"175","author":"Aldoori","year":"2016","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2023.04.023_bib6","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/bjd.15311","article-title":"Frontal fibrosing alopecia in men: an association with facial moisturizers and sunscreens","volume":"177","author":"Debroy Kidambi","year":"2017","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2023.04.023_bib7","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/bjd.17639","article-title":"Identification of titanium dioxide on the hair shaft of patients with and without frontal fibrosing alopecia: a pilot study of 20 patients","volume":"181","author":"Thompson","year":"2019","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2023.04.023_bib8","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jaad.2020.01.026","article-title":"Patch testing and contact allergen avoidance in patients with lichen planopilaris and\/or frontal fibrosing alopecia: a cohort study","volume":"83","author":"Prasad","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2023.04.023_bib9","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1080\/09546634.2020.1774488","article-title":"The efficacy and safety of oral low dose naltrexone versus placebo in the patients with lichen planopilaris: a randomized controlled clinical trial","volume":"33","author":"Lajevardi","year":"2022","journal-title":"J Dermatolog Treat"},{"issue":"6","key":"10.1016\/j.jaad.2023.04.023_bib10","doi-asserted-by":"crossref","first-page":"671","DOI":"10.36849\/JDD.6810","article-title":"Reversible hair loss in lichen planopilaris: regrowth with low-dose naltrexone and platelet-rich plasma","volume":"21","author":"Klein","year":"2022","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2023.04.023_bib11","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1529-8019.2010.01359.x","article-title":"Therapeutic hotline. Effectiveness of the association of cetirizine and topical steroids in lichen planus pilaris\u2013an open-label clinical trial","volume":"23","author":"d\u2019Ovidio R","year":"2010","journal-title":"Dermatol Ther"},{"issue":"3","key":"10.1016\/j.jaad.2023.04.023_bib12","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.jaad.2009.08.054","article-title":"Hydroxychloroquine and lichen planopilaris: efficacy and introduction of Lichen Planopilaris Activity Index scoring system","volume":"62","author":"Chiang","year":"2010","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2023.04.023_bib13","first-page":"829","article-title":"Use of antimalarials in dermatology","volume":"8","author":"Ochsendorf","year":"2010","journal-title":"J Dtsch Dermatol Ges"},{"issue":"12","key":"10.1016\/j.jaad.2023.04.023_bib14","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1001\/jamaophthalmol.2014.3459","article-title":"The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy","volume":"132","author":"Melles","year":"2014","journal-title":"JAMA Ophthalmol"},{"issue":"3","key":"10.1016\/j.jaad.2023.04.023_bib15","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jaad.2009.05.018","article-title":"Efficacy and safety of mycophenolate mofetil for lichen planopilaris","volume":"62","author":"Cho","year":"2010","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2023.04.023_bib16","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s13555-020-00359-x","article-title":"Lichen planopilaris and\u00a0low-level light therapy: four case reports and review of the literature about low-level light therapy and lichenoid dermatosis","volume":"10","author":"Randolph","year":"2020","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"11","key":"10.1016\/j.jaad.2023.04.023_bib17","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1001\/archdermatol.2011.335","article-title":"Low-dose excimer 308-nm laser for treatment of lichen planopilaris","volume":"147","author":"Navarini","year":"2011","journal-title":"Arch Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2023.04.023_bib18","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.jaad.2022.04.054","article-title":"A prospective pilot study of narrowband UV-B treatment of lichen planopilaris","volume":"87","author":"Pathoulas","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2023.04.023_bib19","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1080\/09546634.2020.1755416","article-title":"Mycophenolate mofetil and lichen planopilaris: systematic review and meta-analysis","volume":"33","author":"Mostafa","year":"2022","journal-title":"J Dermatolog Treat"},{"issue":"8","key":"10.1016\/j.jaad.2023.04.023_bib20","doi-asserted-by":"crossref","first-page":"e15625","DOI":"10.1111\/dth.15625","article-title":"Clinical efficacy of mychophenolate mofetil in\u00a0treating lichen planopilaris","volume":"35","author":"Azizpour","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaad.2023.04.023_bib21","doi-asserted-by":"crossref","first-page":"3792489","DOI":"10.1155\/2022\/3792489","article-title":"Comparative efficacy study combination of oral methotrexate and prednisolone versus oral methotrexate in patients with lichen planopilaris","volume":"2022","author":"Fatemi","year":"2022","journal-title":"Dermatol Res Pract"},{"key":"10.1016\/j.jaad.2023.04.023_bib22","doi-asserted-by":"crossref","first-page":"106765","DOI":"10.1016\/j.intimp.2020.106765","article-title":"Cyclosporine or methotrexate, which one is more promising in the treatment of lichen planopilaris? A comparative clinical trial","volume":"86","author":"Fatemi Naeini","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jaad.2023.04.023_bib23","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jdcr.2022.07.038","article-title":"Reversible hair loss in a patient with cicatricial alopecia: a case of regrowth associated with pioglitazone use","volume":"28","author":"Karim","year":"2022","journal-title":"JAAD Case Rep"},{"issue":"11","key":"10.1016\/j.jaad.2023.04.023_bib24","doi-asserted-by":"crossref","first-page":"e15868","DOI":"10.1111\/dth.15868","article-title":"Efficacy and safety of oral pioglitazone in the management of lichen planopilaris in comparison with clobetasol: a randomized clinical trial","volume":"35","author":"Lajevardi","year":"2022","journal-title":"Dermatol Ther"},{"issue":"12","key":"10.1016\/j.jaad.2023.04.023_bib25","first-page":"1276","article-title":"Response of lichen planopilaris to pioglitazone hydrochloride","volume":"18","author":"Peterson","year":"2019","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2023.04.023_bib26","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/j.jaad.2020.09.093","article-title":"Effectiveness of dutasteride in a large series of patients with frontal fibrosing alopecia in real clinical practice","volume":"84","author":"Pindado-Ortega","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2023.04.023_bib27","doi-asserted-by":"crossref","first-page":"e12656","DOI":"10.1111\/dth.12656","article-title":"Tofacitinib for the treatment of lichen planopilaris: A case series","volume":"31","author":"Yang","year":"2018","journal-title":"Dermatol Ther"},{"issue":"5","key":"10.1016\/j.jaad.2023.04.023_bib28","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.jaad.2020.05.104","article-title":"Tofacitinib in the treatment of lichen planopilaris: A retrospective review","volume":"83","author":"Plante","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2023.04.023_bib29","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jaad.2013.12.003","article-title":"Frontal fibrosing alopecia: A multicenter review of 355 patients","volume":"70","author":"Va\u00f1\u00f3-Galv\u00e1n","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2023.04.023_bib30","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1046\/j.1365-2133.1999.02675.x","article-title":"Folliculitis decalvans including tufted folliculitis: clinical, histological and therapeutic findings","volume":"140","author":"Powell","year":"1999","journal-title":"Br J Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096222300720X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096222300720X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:28:14Z","timestamp":1759274894000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S019096222300720X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S019096222300720X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2023.04.023","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment modalities for lymphocytic and neutrophilic scarring alopecia","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2023.04.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}